Key result
High serum M2BP is linked to sharply increased liver-related events and cancer in NAFLD.
Cohort (n=353)
Answers are grounded in this paper and cite their sources.
We previously demonstrated that Mac-2 binding protein (M2BP) is a useful biomarker for nonalcoholic fatty liver disease (NAFLD), particularly NAFLD fibrosis prediction. In the present study, we investigated the prognostic value of M2BP in patients with NAFLD. A total of 506 patients with biopsy-confirmed NAFLD from 2002 to 2013 were enrolled in this study in Japan. Three hundred fifty-three of these patients with NAFLD were available for follow-up for more than 100 days and showed no liver-related events at the time of entry. Liver-related events were defined as hepatocellular carcinoma (HCC), decompensation, and gastroesophageal varices with variceal treatment. The mean follow-up duration of all the subjects was 2716 ± 1621 days (102-7483 days). Eighteen patients developed new liver-related events (HCC, 8; decompensation, 11; varices, 8). Nine patients developed cardiovascular disease (CVD), and 24 patients developed new cancers in other organs. The median serum M2BP level was 1.603 μg/mL, and we divided our cohort into two groups according to the serum M2BP level: M2BP low group (M2BP Low) and M2BP high group (M2BP Hi). The incidence of HCC was significantly higher in M2BP Hi (n = 8) than in M2BP Low (n = 0). The incidence of liver-related events was significantly higher in M2BP Hi (n = 16) than in M2BP Low (n = 2). The incidences of death, CVD events, and cancer in other organs were not different between the groups. Interestingly, the incidence of colorectal cancer was significantly higher in M2BP Hi (n = 5) than in M2BP Low (n = 0). Conclusion: M2BP is a useful biomarker to predict liver-related events, particularly HCC. Additionally, M2BP is a potential predictive biomarker of colorectal cancer development.
No takes yet. Share an insight, caveat, or question.
Kamada et al. (2022) conducted a cohort in Nonalcoholic fatty liver disease (NAFLD) (n=353). High serum Mac-2 binding protein (M2BP Hi; median 1.603 μg/mL) vs. Low serum Mac-2 binding protein (M2BP Low) was evaluated on Liver-related events (hepatocellular carcinoma, decompensation, and gastroesophageal varices with variceal treatment). High serum Mac-2 binding protein (M2BP) significantly increased liver-related events (16 vs 2 cases), HCC (8 vs 0), and colorectal cancer (5 vs 0) compared to low M2BP in NAFLD patients.
Synapse has enriched 10 related papers. Consider them for comparative context: